AU2020272467A1 - Hexahydro-1H-pyrazino(1,2-a)pyrazine compounds for the treatment of autoimmune disease - Google Patents
Hexahydro-1H-pyrazino(1,2-a)pyrazine compounds for the treatment of autoimmune disease Download PDFInfo
- Publication number
- AU2020272467A1 AU2020272467A1 AU2020272467A AU2020272467A AU2020272467A1 AU 2020272467 A1 AU2020272467 A1 AU 2020272467A1 AU 2020272467 A AU2020272467 A AU 2020272467A AU 2020272467 A AU2020272467 A AU 2020272467A AU 2020272467 A1 AU2020272467 A1 AU 2020272467A1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- hexahydro
- pyrazin
- pyrazino
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/081900 | 2019-04-09 | ||
| CN2019081900 | 2019-04-09 | ||
| CNPCT/CN2019/121598 | 2019-11-28 | ||
| CN2019121598 | 2019-11-28 | ||
| CN2020078225 | 2020-03-06 | ||
| CNPCT/CN2020/078225 | 2020-03-06 | ||
| PCT/EP2020/059831 WO2020207991A1 (en) | 2019-04-09 | 2020-04-07 | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020272467A1 true AU2020272467A1 (en) | 2021-10-14 |
Family
ID=70228042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020272467A Abandoned AU2020272467A1 (en) | 2019-04-09 | 2020-04-07 | Hexahydro-1H-pyrazino(1,2-a)pyrazine compounds for the treatment of autoimmune disease |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220340597A1 (https=) |
| EP (1) | EP3953356B1 (https=) |
| JP (1) | JP7692838B2 (https=) |
| KR (1) | KR20210149163A (https=) |
| CN (1) | CN113710672B (https=) |
| AU (1) | AU2020272467A1 (https=) |
| BR (1) | BR112021020297A2 (https=) |
| CA (1) | CA3135129A1 (https=) |
| CL (1) | CL2021002621A1 (https=) |
| CO (1) | CO2021013166A2 (https=) |
| CR (1) | CR20210513A (https=) |
| IL (1) | IL286870A (https=) |
| MA (1) | MA55594A (https=) |
| MX (1) | MX2021012223A (https=) |
| PE (1) | PE20212178A1 (https=) |
| PH (1) | PH12021552533A1 (https=) |
| SG (1) | SG11202110401WA (https=) |
| TW (1) | TW202104230A (https=) |
| WO (1) | WO2020207991A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021084022A1 (en) * | 2019-10-31 | 2021-05-06 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| CN114728959B (zh) * | 2019-11-12 | 2024-11-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-b]异喹啉化合物 |
| US12503471B2 (en) | 2019-11-19 | 2025-12-23 | Hoffmann-La Roche Inc. | Triazatricycle compounds for the treatment of autoimmune disease |
| CN114728976B (zh) | 2019-11-19 | 2024-08-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物 |
| KR20220122637A (ko) | 2019-11-28 | 2022-09-02 | 바이엘 악티엔게젤샤프트 | 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론 |
| WO2021110614A1 (en) * | 2019-12-03 | 2021-06-10 | F. Hoffmann-La Roche Ag | HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE |
| US20240317735A1 (en) * | 2020-07-14 | 2024-09-26 | Hoffmann-La Roche Inc. | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103562201B (zh) * | 2011-01-12 | 2016-10-19 | 帆德制药股份有限公司 | 作为toll样受体调节剂的取代的苯并氮杂卓 |
| RS56747B1 (sr) | 2012-09-14 | 2018-03-30 | Hoffmann La Roche | Pirazol derivati karboksamida kao taar modulatori za upotrebu u lečenju nekoliko poremećaja, kao što su depresija, dijabetes i parkinsonova bolest |
| CN105992766A (zh) * | 2013-12-13 | 2016-10-05 | 武田药品工业株式会社 | 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物 |
| CA3005766A1 (en) | 2015-12-17 | 2017-06-22 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| EP3807271A1 (en) * | 2018-06-13 | 2021-04-21 | F. Hoffmann-La Roche AG | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease |
| JP2022501401A (ja) * | 2018-09-27 | 2022-01-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の治療のためのヘテロシクリル化合物 |
-
2020
- 2020-04-07 MX MX2021012223A patent/MX2021012223A/es unknown
- 2020-04-07 MA MA055594A patent/MA55594A/fr unknown
- 2020-04-07 CA CA3135129A patent/CA3135129A1/en active Pending
- 2020-04-07 CN CN202080030189.2A patent/CN113710672B/zh active Active
- 2020-04-07 CR CR20210513A patent/CR20210513A/es unknown
- 2020-04-07 BR BR112021020297A patent/BR112021020297A2/pt not_active Application Discontinuation
- 2020-04-07 SG SG11202110401WA patent/SG11202110401WA/en unknown
- 2020-04-07 AU AU2020272467A patent/AU2020272467A1/en not_active Abandoned
- 2020-04-07 PH PH1/2021/552533A patent/PH12021552533A1/en unknown
- 2020-04-07 PE PE2021001647A patent/PE20212178A1/es unknown
- 2020-04-07 JP JP2021559754A patent/JP7692838B2/ja active Active
- 2020-04-07 EP EP20717841.9A patent/EP3953356B1/en active Active
- 2020-04-07 KR KR1020217036391A patent/KR20210149163A/ko not_active Withdrawn
- 2020-04-07 WO PCT/EP2020/059831 patent/WO2020207991A1/en not_active Ceased
- 2020-04-07 US US17/602,057 patent/US20220340597A1/en not_active Abandoned
- 2020-04-08 TW TW109111749A patent/TW202104230A/zh unknown
-
2021
- 2021-09-30 CO CONC2021/0013166A patent/CO2021013166A2/es unknown
- 2021-09-30 IL IL286870A patent/IL286870A/en unknown
- 2021-10-06 CL CL2021002621A patent/CL2021002621A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021552533A1 (en) | 2022-06-20 |
| CN113710672A (zh) | 2021-11-26 |
| EP3953356A1 (en) | 2022-02-16 |
| CO2021013166A2 (es) | 2021-12-10 |
| SG11202110401WA (en) | 2021-10-28 |
| CR20210513A (es) | 2021-11-02 |
| IL286870A (en) | 2021-10-31 |
| TW202104230A (zh) | 2021-02-01 |
| WO2020207991A1 (en) | 2020-10-15 |
| KR20210149163A (ko) | 2021-12-08 |
| BR112021020297A2 (pt) | 2021-12-14 |
| CA3135129A1 (en) | 2020-10-15 |
| PE20212178A1 (es) | 2021-11-09 |
| CN113710672B (zh) | 2025-01-03 |
| EP3953356B1 (en) | 2023-07-26 |
| US20220340597A1 (en) | 2022-10-27 |
| MA55594A (fr) | 2022-02-16 |
| JP2022527588A (ja) | 2022-06-02 |
| JP7692838B2 (ja) | 2025-06-16 |
| CL2021002621A1 (es) | 2022-05-13 |
| MX2021012223A (es) | 2021-11-03 |
| EP3953356C0 (en) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3953356B1 (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| EP3802539B1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| US12486273B2 (en) | Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| TW202024065A (zh) | 用於治療自體免疫疾病之雜環基化合物 | |
| EP4051387B1 (en) | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | |
| EP3623369B1 (en) | Novel morpholinyl amine compounds for the treatment of autoimmune disease | |
| US12503471B2 (en) | Triazatricycle compounds for the treatment of autoimmune disease | |
| HK40055574B (zh) | 用於治疗自身免疫性疾病的六氢-1h-吡嗪幷[1，2- a]吡嗪化合物 | |
| HK40055574A (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| CA3285578A1 (en) | New e3 ubiquitin ligase ligand, protein degradation agent and use thereof | |
| HK40068905B (zh) | 用於治疗自身免疫性疾病的氢吡嗪并[1，2-d][1，4]二氮杂䓬化合物 | |
| HK40068905A (en) | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | |
| HK40071775A (en) | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |